|01/18/18||Xtant Medical Enters into Restructuring and Exchange Agreement with All Holders of Outstanding Convertible Notes|
|Conversion of $1.627M (plus interest) of convertible notes into common stock
Exchange of $70.238M (plus interest) of convertible notes into common stock
Upon stockholder approval, amendment of Certificate of Incorporation to effect reverse stock split of common stock
Private placement of approximately $6.809M of common stock
Completion of transaction anticipated to allow Xtant to meet liquidity needs and reposition itself for long-term growth.
BELGRADE, Mont., Jan. 18, 2018 (G... |
|11/21/17||Xtant Medical Reports Third Quarter 2017 Financial Results|
|Company restructuring efforts continue to gain traction towards profitability
Third Quarter 2017 Highlights
Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported during the third quarter of 2016
Operating Expenses decreased 17% to $14.9 million, compared to $17.9 million reported during the third quarter of 2016
Third quarter 2017 EBITDA of $1.4 million compared to $0.7 million reported during the third quarter of 2016
Company management to host... |
|11/09/17||Xtant Medical Postpones Release of Third Quarter 2017 Financial Results|
|BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017.
The Company now plans to release its third quarter 2017 financial results in conjunction with... |
|11/01/17||Xtant Medical Enters into a Distribution Agreement with curasan, Inc. Bringing Matriform™ to Market|
|BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc. adding a premium line of synthetic scaffolds to its biologics portfolio.
Matriform, Xtant’s brand of the curasan synthetic product portfolio for orthopedic applications, consists of a composition of pure phase Beta-Tricalcium Pho... |